RESUMO
Cardiovascular morbidity and mortality are several-fold higher in patients with advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD) than in the general population. Hyperhomocysteinemia has undoubtedly a central role in such a prominent cardiovascular burden. The levels of homocysteine are regulated by methyl donors (folate, methionine, choline, betaine), and cofactors (vitamin B6, vitamin B12,). Uremia-induced hyperhomocysteinemia has as its main targets DNA methyltransferases, and this leads to an altered epigenetic control of genes regulated through methylation. In renal patients, the epigenetic landscape is strictly correlated with the uremic phenotype and dependent on dietary intake of micronutrients, inflammation, gut microbiome, inflammatory status, oxidative stress, and lifestyle habits. All these factors are key contributors in methylome maintenance and in the modulation of gene transcription through DNA hypo- or hypermethylation in CKD. This is an overview of the epigenetic changes related to DNA methylation in patients with advanced CKD and ESRD. We explored the currently available data on the molecular dysregulations resulting from altered gene expression in uremia. Special attention was paid to the efficacy of B-vitamins supplementation and dietary intake of methyl donors on homocysteine lowering and cardiovascular protection.
Assuntos
Betaína/administração & dosagem , Colina/administração & dosagem , Metilação de DNA/genética , Suplementos Nutricionais , Ingestão de Alimentos/fisiologia , Epigênese Genética , Ácido Fólico/administração & dosagem , Metionina/administração & dosagem , Fenômenos Fisiológicos da Nutrição/genética , Insuficiência Renal Crônica/genética , Insuficiência Renal Crônica/metabolismo , Vitamina B 12/administração & dosagem , Vitamina B 6/administração & dosagem , Doenças Cardiovasculares/etiologia , Doenças Cardiovasculares/prevenção & controle , Humanos , Hiper-Homocisteinemia/etiologia , Hiper-Homocisteinemia/prevenção & controle , Falência Renal Crônica , Fenômenos Fisiológicos da Nutrição/fisiologia , Insuficiência Renal Crônica/complicações , Uremia/complicações , Uremia/genéticaRESUMO
AIM: Ghrelin can act as a signal for meal initiation and play a role in the regulation of gastrointestinal (GI) motility via hypothalamic circuit. This study investigated the correlation between changes of hypothalamic ghrelin system and GI motility dysfunction and anorexia in rats with chronic renal failure (CRF). METHODS: Sprague-Dawley (SD) rats (male/female 1:1, 180 ± 20 g) were randomly classified into a CRF group and control group (n = 8 per group). 5/6 nephrectomy was used to construct the CRF model. When plasma creatinine concentration (PCr) and blood urea nitrogen (BUN) in the CRF group were twice higher than the normal, food intake (g/24 h) and gastrointestinal interdigestive myoelectric complex (IMC) were detected. Then all rats were killed for assessment of the mRNA expression of ghrelin and growth hormone secretagogue receptor (GHS-R) in hypothalamus using reverse transcription-polymerase chain reaction. Analysis of variance, Student-Newman-Keuls-q-test and Correlation Analysis were used to do statistical analysis. P < 0.05 was considered as statistically significant. RESULTS: Compared to the control group, the CRF group was obviously decreased in the food intake (g/24 h), the phase III duration and amplitude and the ghrelin and GHS-R expression in the hypothalamus (P < 0.05). There was a positive correlation between them (P < 0.05). CONCLUSION: Changes of ghrelin and GHS-R in the hypothalamus correlate with gastrointestinal motility dysfunction and anorexia in rats with CRF.
Assuntos
Anorexia/etiologia , Gastroenteropatias/etiologia , Motilidade Gastrointestinal , Grelina/metabolismo , Hipotálamo/metabolismo , Falência Renal Crônica/complicações , Uremia/etiologia , Animais , Anorexia/genética , Anorexia/metabolismo , Anorexia/fisiopatologia , Biomarcadores/sangue , Nitrogênio da Ureia Sanguínea , Creatinina/sangue , Modelos Animais de Doenças , Ingestão de Alimentos , Feminino , Gastroenteropatias/genética , Gastroenteropatias/metabolismo , Gastroenteropatias/fisiopatologia , Grelina/genética , Hipotálamo/fisiopatologia , Falência Renal Crônica/genética , Falência Renal Crônica/metabolismo , Falência Renal Crônica/fisiopatologia , Masculino , Complexo Mioelétrico Migratório , RNA Mensageiro/metabolismo , Ratos , Ratos Sprague-Dawley , Receptores de Grelina/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Fatores de Tempo , Uremia/genética , Uremia/metabolismo , Uremia/fisiopatologiaRESUMO
Klotho is a protein of significant importance for mineral homeostasis. It helps to increase parathyroid hormone (PTH) secretion and in the trafficking of Na+/K+-ATPase to the cell membrane; however, it is also a cofactor for fibroblast growth factor (FGF)-23 to interact with its receptor, FGFR1 IIIC, resulting in decreased PTH secretion. Studies on the regulation of parathyroid klotho expression in uremia have provided varying results. To help resolve this, we measured klotho expression in the parathyroid and its response to severe uremia, hyperphosphatemia, and calcitriol treatment in the 5/6 nephrectomy rat model of secondary hyperparathyroidism. Parathyroid klotho gene expression and protein were significantly increased in severely uremic hyperphosphatemic rats, but not affected by moderate uremia and normal serum phosphorus. Calcitriol suppressed klotho gene and protein expression in severe secondary hyperparathyroidism, despite a further increase in plasma phosphate. Both FGFR1 IIIC and Na+/K+-ATPase gene expression were significantly elevated in severe secondary hyperparathyroidism. Parathyroid gland klotho expression and the plasma calcium ion concentration were inversely correlated. Thus, our study suggests that klotho may act as a positive regulator of PTH expression and secretion in secondary hyperparathyroidism.
Assuntos
Glucuronidase/metabolismo , Hiperparatireoidismo Secundário/metabolismo , Hiperfosfatemia/metabolismo , Glândulas Paratireoides/metabolismo , Uremia/metabolismo , Animais , Calcitriol/farmacologia , Cálcio/sangue , Modelos Animais de Doenças , Fatores de Crescimento de Fibroblastos/metabolismo , Glucuronidase/genética , Hiperparatireoidismo Secundário/tratamento farmacológico , Hiperparatireoidismo Secundário/etiologia , Hiperparatireoidismo Secundário/genética , Hiperfosfatemia/etiologia , Hiperfosfatemia/genética , Proteínas Klotho , Masculino , Nefrectomia , Glândulas Paratireoides/efeitos dos fármacos , Hormônio Paratireóideo/sangue , Hormônio Paratireóideo/genética , Fósforo/sangue , RNA Mensageiro/metabolismo , Ratos , Ratos Wistar , Receptor Tipo 1 de Fator de Crescimento de Fibroblastos/genética , Receptores de Calcitriol/genética , Receptores de Detecção de Cálcio/genética , ATPase Trocadora de Sódio-Potássio/genética , Regulação para Cima , Uremia/tratamento farmacológico , Uremia/etiologia , Uremia/genéticaRESUMO
PTH is a major mediator of bone and mineral metabolism. However, physiological and pathological investigations of parathyroid cells (PTCs) have been limited because of the lack of available cell lines and because the organ is too small for detailed studies. Here, we describe a novel method for adenovirus-mediated cDNA transfer into PTCs, and we show the accuracy of the method in a rat model of uremia-induced secondary hyperparathyroidism. Rats underwent a 5/6-nephrectomy and were fed with a high-phosphate diet for 8 wk. The parathyroid glands were surgically exposed and adenoviruses containing LacZ or Ca-sensing receptor (CaSR) were directly injected into the glands under a zoom-stereo microscope. The parathyroid glands were analyzed for infection of adenovirus and immunohistochemically for expression of CaSR. The functional activity of exogenous CaSR in PTCs after this treatment was investigated based on changes of the calcium and PTH curve. A virus concentration of more than 10(9) plaque-forming units/ml was required for adequate infection of PTCs within 7 d after treatment. Marked increase of CaSR-positive PTCs by 2.39 +/- 0.72 times relative to control treatment, and significant colocalization of CaSR overexpression and virus labeling, were observed in glands after gene introduction. The calcium and PTH curve was shifted to the left from the basal position (set point, 1.10 +/- 0.09 to 0.76 +/- 0.12 mm; P < 0.0001), indicating successful introduction of a functionally active cDNA into the PTCs. This technique may facilitate an elucidation of biological effects through targeting and identification of specific features of PTCs, which may provide the basis for new clinical approaches.
Assuntos
DNA Complementar/administração & dosagem , Técnicas de Transferência de Genes , Glândulas Paratireoides/metabolismo , Adenoviridae/genética , Animais , DNA Complementar/análise , DNA Complementar/genética , DNA Complementar/metabolismo , Modelos Animais de Doenças , Etiquetas de Sequências Expressas , Vetores Genéticos/administração & dosagem , Hiperparatireoidismo Secundário/genética , Hiperparatireoidismo Secundário/patologia , Injeções/métodos , Óperon Lac , Modelos Biológicos , Concentração Osmolar , Glândulas Paratireoides/citologia , Ratos , Ratos Sprague-Dawley , Ratos Transgênicos , Receptores de Detecção de Cálcio/administração & dosagem , Receptores de Detecção de Cálcio/genética , Receptores de Detecção de Cálcio/metabolismo , Uremia/genética , Uremia/patologiaRESUMO
BACKGROUND: Fibroblast growth factor 23 (FGF23) regulates renal phosphate reabsorption and 1alpha,25-dihydroxyvitamin D [1,25(OH)(2)D(3)] metabolism. Patients with chronic kidney disease (CKD) have increased levels of circulating FGF23, but the direct regulation of this elevation of FGF23 is incompletely understood. METHOD: We measured plasma parameters in uremic rats fed a high-phosphorus diet and then performed parathyroidectomy (PTX) to determine its effect. We also investigated FGF23 mRNA expression in various tissues to identify the major source of circulating FGF23. RESULT: The uremic rats displayed dramatic changes in plasma FGF23 levels, consistent with increased expression of FGF23 in bone. Elevated FGF23 was associated with phosphate and parathyroid hormone (PTH). After PTX, the elevated FGF23 had decreased, consistent with decreased expression of FGF23 in bone. Significant decreases in plasma FGF23 were associated with PTH and 1,25(OH)(2)D(3), but not phosphate. CONCLUSION: Elevated plasma FGF23 levels in uremic rats reflect the increased expression of FGF23 in bone. The expression of FGF23 in bone may be regulated by a PTH-1,25(OH)(2)D(3) axis-dependent pathway and another PTH-dependent and 1,25(OH)(2)D(3)-independent pathway in uremic rats. The pathway may be decided by the degree of renal dysfunction.
Assuntos
Osso e Ossos/metabolismo , Fatores de Crescimento de Fibroblastos/genética , Uremia/patologia , Animais , Nitrogênio da Ureia Sanguínea , Peso Corporal , Calcitriol/sangue , Dieta , Ensaio de Imunoadsorção Enzimática , Fatores de Crescimento de Fibroblastos/sangue , Perfilação da Expressão Gênica , Masculino , Nefrectomia , Hormônio Paratireóideo/sangue , Paratireoidectomia , Fósforo/administração & dosagem , Fósforo/sangue , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Ratos , Ratos Sprague-Dawley , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Fatores de Tempo , Uremia/sangue , Uremia/genéticaRESUMO
Although the role of reactive oxygen species (ROS) in chronic renal failure (CRF) is not definitely demonstrated, a consistent number of observations has provided evidence for the presence of oxidative stress in uremic patients undergoing maintenance dialysis. In order to investigate this hypothesis further and to understand the role of antioxidant supplementation, peripheral blood lymphocytes were taken from 36 dialysis patients before and after Vitamin E supplementation in a dosage of 600 mg per day (2x300 mg) for 14 weeks and examined in the alkaline Comet assay for DNA strand breakage. The results were also compared with those of 36 controls with comparable age, sex, and smoking habits, and with no history of renal disease. The DNA breakage observed in the lymphocytes of patients before Vitamin E supplementation was significantly higher than in the controls (P<0.001) but a clear protective effect of Vitamin E supplementation were observed after 14 weeks of therapy.